As of 12:19:08 PM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,743.0640
4,743.0640
4,023.4970
3,335.1990
1,915.4660
Operating Expense
27,013.8910
27,013.8910
27,122.8050
18,336.8090
10,784.3090
Operating Income
-22,270.8270
-22,270.8270
-23,099.3080
-15,001.6100
-8,868.8430
Net Non Operating Interest Income Expense
504.4120
504.4120
-109.7810
-135.1780
-109.2450
Pretax Income
-21,766.4130
-21,766.4130
-23,209.0900
-15,136.7890
-8,978.0890
Tax Provision
296.9910
296.9910
--
--
--
Net Income Common Stockholders
-22,063.4040
-22,063.4040
-23,209.0900
-15,136.7890
-8,978.0890
Diluted NI Available to Com Stockholders
-22,063.4040
-22,063.4040
-23,209.0900
-15,136.7890
-8,978.0890
Basic EPS
-0.17
-0.17
-0.29
-0.19
-0.15
Diluted EPS
-0.17
-0.17
-0.29
-0.19
-0.15
Basic Average Shares
133,422.5580
133,422.5580
79,837.0840
79,691.3580
60,760.9520
Diluted Average Shares
133,422.5580
133,422.5580
79,837.0840
79,691.3580
60,760.9520
Total Operating Income as Reported
-22,310.6280
-22,310.6280
-23,136.6480
-15,024.5970
-8,889.2200
Rent Expense Supplemental
52.0960
52.0960
32.9360
111.7470
117.5190
Total Expenses
27,013.8910
27,013.8910
27,122.8050
18,336.8090
10,784.3090
Net Income from Continuing & Discontinued Operation
-22,063.4040
-22,063.4040
-23,209.0900
-15,136.7890
-8,978.0890
Normalized Income
-22,063.4040
-22,063.4040
-23,209.0900
-15,136.7890
-8,978.0890
Interest Income
718.1130
718.1130
95.5720
53.5520
43.4280
Interest Expense
173.8990
173.8990
168.0140
165.7440
132.2960
Net Interest Income
504.4120
504.4120
-109.7810
-135.1780
-109.2450
EBIT
-21,592.5140
-21,592.5140
-23,041.0760
-14,971.0450
-8,845.7930
EBITDA
-21,326.3200
-21,326.3200
-22,275.1510
-14,475.5270
-8,533.8490
Reconciled Depreciation
266.1940
266.1940
765.9250
495.5180
311.9440
Net Income from Continuing Operation Net Minority Interest
-22,063.4040
-22,063.4040
-23,209.0900
-15,136.7890
-8,978.0890
Normalized EBITDA
-21,326.3200
-21,326.3200
-22,275.1510
-14,475.5270
-8,533.8490
Tax Rate for Calcs
0.0003
0.0003
--
--
--
12/31/2020 - 4/21/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ABVX.PA ABIVAX Société Anonyme
7.35
+4.11%
TNG.PA Transgene SA
0.7020
0.00%
4BB.L 4basebio PLC
1,185.00
0.00%
HPHA.DE Heidelberg Pharma AG
2.2000
-3.08%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
172.500
-3.42%
MDG1.DE Medigene AG
1.0180
-1.17%
ACHFF Arch Biopartners Inc.
1.2100
+0.83%
IVA Inventiva S.A.
2.3500
-2.49%
IMMU.ST Mendus AB (publ)
8.85
+4.57%
ALTME.PA TME Pharma N.V.
0.0730
-3.95%